SPTBN1 and hepatocellular carcinoma: Targeting βII-Spectrin (SPTBN1) in a tissue-specific manner offers a promising avenue for managing obesity and its complications, including progression to liver diseases and HCC (Rao et al. 2021; Yang et al. 2024).